Citi downgraded Healthpeak (PEAK) to Neutral from Buy with a $23 price target. The analyst continues to have a favorable view on life science, but prefers to get life science exposure through Alexandria Real Estate (ARE) given its greater scale, tenant, and geographic diversity. Citi sees some risks for Healthpeak’s life science portfolio that "could be potential issues," including its small-cap and private biotech exposure and concentration in San Francisco. Additionally, internal growth upside for Healthpeak’s life science portfolio is more limited, given higher occupancies and lower near-term lease roll, contends Citi.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PEAK:
- Healthpeak downgraded at Scotiabank on Life Science segment’s tougher outlook
- Healthpeak downgraded to Sector Perform from Outperform at Scotiabank
- Healthpeak announces closing of holding company reorganization
- Healthpeak sees FY23 adjusted FFO $1.70-$1.76, consensus $1.79
- Healthpeak reports Q4 adjusted FFO 44c, consensus 43c
